Company / EPS (Basic)
Aclaris Therapeutics, Inc. EPS (Basic) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$1.71
FY2025
5-year range
-$3.90 / -$1.20
FY2021-FY2025
Trend
-34.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Basic) has fluctuated over the past 5 years, ranging from $-3.90 in FY2021 to $-1.20 in FY2022.
Based on SEC 10-K filings.
-1.71 in FY2025.
Declined from $-1.60 to $-1.71 over the past 2 years.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (basic) decreased 34.6% year-over-year.
- Peak eps (basic) was recorded in FY2022.
- Lowest eps (basic) in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.71 | -34.6% |
| FY2024 | -$1.27 | +20.6% |
| FY2023 | -$1.60 | -33.3% |
| FY2022 | -$1.20 | +69.2% |
| FY2021 | -$3.90 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026